Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
about
Prevention of Alzheimer's diseaseHuperzine A for mild cognitive impairmentHuperzine A for mild cognitive impairmentCadaverine's Functional Role in Plant Development and Environmental ResponseThe pharmacology and therapeutic potential of (-)-huperzine A.Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysisCholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's diseaseAlternative medicine and Alzheimer diseaseNovel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors.Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease.Huperzine A protects neural stem cells against Aβ-induced apoptosis in a neural stem cells and microglia co-culture system.Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease.Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.Acetylcholinesterase inhibitors from plants and fungi.Caffeine inhibits acetylcholinesterase, but not butyrylcholinesteraseAn update on huperzine A as a treatment for Alzheimer's disease.Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies.Compound danshen tablet ameliorated aβ25-35-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins.Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis.Neurogenic Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer's Disease.Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment.Cholinesterase inhibitors from botanicals.Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Quinolizidine alkaloid biosynthesis: recent advances and future prospectsA computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.Synthesis and biological evaluation of 3,6-diaryl-7H-thiazolo[3,2-b] [1,2,4]triazin-7-one derivatives as acetylcholinesterase inhibitors.Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.Study of acetylcholinesterase inhibitors using CE with contactless conductivity detection.Synthesis of α-oxycarbanilinophosphonates and their anticholinesterase activities: the most potent derivative is bound to the peripheral site of acetylcholinesterase.Effects of Yizhi Capsule on learning and memory disorder and beta-amyloid peptide induced neurotoxicity in rats.Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice.Novel Method of Preparation and Activity Research on Arctigenin from Fructus Arctii.A robust and scalable synthesis of the potent neuroprotective agent (−)-huperzine ANanoparticles for the Treatment of Alzheimer's Disease: Theoretical Rationale, Present Status and Future PerspectivesEASY ACCESS TO 4-SUBSTITUTED (±)-HUPERZINE A ANALOGUESDesign, Synthesis, and Acetylcholinesterase Inhibition Assay of Novel 9-(1-(Substituted-benzyl)piperidin-4-yl)-2-chloro-9H-purin-6-amine DerivativesSelagoline, A new Alkaloid fromHuperzia Selago
P2860
Q22248031-4E853C95-1D38-4FD7-8F91-8FF6E0043DAEQ24202101-A73F70C3-D539-4DA6-8E87-D3E165A9EDE0Q24234330-E6C356DC-43AA-4140-9ED5-172B5920B95AQ26742152-5682B178-A782-4F8E-9C8B-CEA8A9E26D72Q27691305-468D55EC-7378-476B-8B79-A038D00CEB98Q28235342-14EF5D8C-0B57-40AC-A320-28B79E4B59A0Q28287090-B9EB0B92-1064-4FB8-903D-0C33372CED0FQ28751860-E01E1BFD-7986-403A-9A02-53685FA121DCQ33552783-11518C3C-0C14-41F9-8589-D93DBC3D7824Q34993154-30EF2F05-7094-410F-994E-C4F45B6F6377Q35919007-087F141F-027E-4107-AD77-F06AA9ACBCD0Q36163354-45853FCA-3281-40BE-843F-9EAEAC7E5F85Q36349629-6B22CED2-1D1A-44FD-ACDA-523A7295FC19Q36435217-9B6DA5CE-0B40-475E-9E3D-8CD0452B32EEQ36913687-2A3C3126-E04C-4C7C-A5FE-790BD63CC0CEQ37071192-B10A5C8F-0434-404F-95F6-6CCD98CD572FQ37106942-4273549D-0B9A-4345-B34C-6A783DB4A12DQ37502879-28E8F989-CD60-4734-9ED9-C4EF14D2A091Q37594755-06EED79E-8417-4944-9D36-965E15754941Q37690692-5CA64742-6969-4D98-8913-58C6D2096E70Q38162960-B58569DA-47D0-42A4-BD43-8E272300BC9FQ38172097-5B38817C-C900-44ED-8E9F-D964EC1212E0Q38217301-658EA0A9-F16E-4F33-9C1E-3F0168CF318FQ39038234-B38890FB-68AF-40F6-8A45-A4041E3AF36FQ39527906-C7E385B3-D990-470A-A6EB-06B811842FFFQ42148589-F120D48F-058C-4C37-B137-4E1C122C1101Q42721755-6EDA2878-BE7B-491D-88AD-D6E264BC1DBFQ42835910-6B4CB589-29D2-46EB-B556-D5737E427755Q43102438-4C3C5D24-53FE-4B2F-8FDF-DE189C0049DFQ43275974-9548C8E2-087B-4B95-BF3D-757BCB2F1489Q45736913-3A1E0AA1-7058-45D5-820F-57CF74CAD725Q48487380-93CCFFA2-831A-4DDB-9A9A-953619DB87AEQ50730121-A2618FA5-930D-4405-AFFF-293B683CC066Q52632652-CD2CBE5D-872F-4B3F-BC38-919F3850C49FQ56700260-0E8D7859-F389-47A6-B176-2B16EA830404Q57341564-99454D43-5DC4-4991-A684-5E4B8D299B64Q58856706-EBBE5010-19F6-45ED-A474-E8187551A645Q59008707-506D7BC3-C061-4AA8-A4C2-B8DA14703A05Q59156036-97727191-B2D7-47D0-A0DA-296A9FC7419C
P2860
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@ast
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@en
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@nl
type
label
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@ast
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@en
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@nl
prefLabel
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@ast
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@en
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@nl
P2093
P3181
P356
P1476
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
@en
P2093
P304
P3181
P356
10.2174/0929867003375281
P407
P577
2000-03-01T00:00:00Z